Nexalis Therapeutics Limited

A$0.01As of Sun 8 Nov 2026, 12:00 UTC
ASX:NX1Healthcare
Country Australia
PE (Fwd) •••
TSR 10Y CAGR (31.41%)
Div yield —
ROE —
Biotechnology
Beta (5Y) (0.06)
PE TTM —
TSR TTM (75.58%)
Mkt cap A$2.024M
ROIC —
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.0091
13.70%
(39.18%)
Sell 3|9|7|7|9
4Q25
1Q26
2Q26
3Q26
Earnings per share$
—
—
—
—
10.58%
14.51%
15.12%
18.98%
Revenue$M
0.247
0.247
0.257
0.272
7.48%
4.70%
12.04%
14.34%
Peers (US$1.390M)
Cap (US$)
PE
1.436M
—
Capital
TTM
5Y
10Y
Leveragex
1.163
—
—
EBIT/Intx
4.167
0.417
0.402
Own earn%
31.89
51.91
55.36
Sh yield%
37.83
37.06
33.52
Owners
Insiders/Inst%
11.44
67.95
Short interest%
3.76
SBC / revenue%
5.61
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
19
Op margin range%
29–34
$1 testx
−0.1
Incr. ROIC%
21